STOCK TITAN

[144] SOPHiA GENETICS SA SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

SOPHiA GENETICS SA (SOPH) filing a Form 144 notifies a proposed sale of 6,833 common shares with an aggregate market value of $30,543.51 to be sold approximately on 10/03/2025 on NASDAQ. The shares were acquired as Restricted Stock Units on 10/02/2025 from the issuer and payment was recorded on 10/02/2025. The filing shows the seller previously completed Rule 10b5-1 sales totaling 5,337 shares across five transactions from 07/07/2025 through 09/19/2025, generating gross proceeds shown per transaction. The Form 144 includes the seller's representation that no undisclosed material adverse information exists and conforms to Rule 144 disclosure requirements.

SOPHiA GENETICS SA (SOPH) presenta un modulo Form 144 che segnala una vendita proposta di 6.833 azioni ordinarie per un valore di mercato aggregato di 30.543,51 USD da vendere circa il 03/10/2025 su NASDAQ. Le azioni sono state acquisite come Restricted Stock Units il 02/10/2025 dall'emittente e il pagamento è stato registrato il 02/10/2025. La presentazione mostra che il venditore ha precedentemente completato vendite ai sensi della Rule 10b5-1 per un totale di 5.337 azioni attraverso cinque transazioni dal 07/07/2025 al 19/09/2025, generando proventi lordi indicati per transazione. Il Form 144 include la dichiarazione del venditore che non esistono informazioni materiali avverse non divulgate e si conforma ai requisiti di disclosure della Rule 144.
SOPHiA GENETICS SA (SOPH) presenta un Formulario 144 que notifica una venta propuesta de 6,833 acciones ordinarias con un valor de mercado agregado de 30,543.51 USD a venderse aproximadamente el 03/10/2025 en NASDAQ. Las acciones se adquirieron como Restricted Stock Units el 02/10/2025 del emisor y el pago se registró el 02/10/2025. La presentación muestra que el vendedor previamente completó ventas según la Regla 10b5-1 por un total de 5,337 acciones en cinco transacciones desde el 07/07/2025 al 19/09/2025, con los ingresos brutos mostrados por cada transacción. El Formulario 144 incluye la declaración del vendedor de que no existen informaciones materiales adversas no divulgadas y cumple con los requisitos de divulgación de la Regla 144.
SOPHiA GENETICS SA (SOPH)는 Form 144를 제출하며 NASDAQ에서 약 10/03/2025에 매도될 예정인 6,833주의 보통주를 총시장가치 30,543.51달러로 제시합니다. 이 주식은 발행회사로부터 2025년 10월 2일에 Restricted Stock Units로 취득되었고, 대금은 2025년 10월 2일에 기록되었습니다. 신고서는 매도인이 이전에 2025년 7월 7일부터 2025년 9월 19일까지 다섯 건에 걸친 5,337주에 대한 Rule 10b5-1 매도를 완료했으며, 거래별로 총 수익이 제시되어 있음을 보여줍니다. Form 144에는 매도인이 비공개의 주요 악재 정보가 존재하지 않는다는 진술이 포함되어 있으며 Rule 144 공시 요건에 부합합니다.
SOPHiA GENETICS SA (SOPH) dépose un formulaire Form 144 qui notifie une vente proposée de 6 833 actions ordinaires d'une valeur marchande globale de 30 543,51 USD à vendre approximativement le 03/10/2025 sur le NASDAQ. Les actions ont été acquises sous forme de Restricted Stock Units le 02/10/2025 auprès de l’émetteur et le paiement a été enregistré le 02/10/2025. Le dépôt indique que le vendeur a précédemment effectué des ventes en vertu de la règle 10b5-1 totalisant 5 337 actions réparties sur cinq transactions du 07/07/2025 au 19/09/2025, générant les produits bruts indiqués par transaction. Le Form 144 comprend la déclaration du vendeur selon laquelle il n’existe aucune information matérielle défavorable non divulguée et est conforme aux exigences de divulgation de la règle 144.
SOPHiA GENETICS SA (SOPH) reicht ein Formular Form 144 ein, das einen vorgeschlagenen Verkauf von 6.833 Stammaktien mit einem Gesamtsmarktwert von 30.543,51 USD ankündigt, der voraussichtlich am 03.10.2025 an der NASDAQ verkauft wird. Die Aktien wurden am 02.10.2025 vom Emittenten als Restricted Stock Units erworben und die Zahlung wurde am 02.10.2025 verbucht. Die Einreichung zeigt, dass der Verkäufer zuvor Rule 10b5-1-Verkäufe in Höhe von insgesamt 5.337 Aktien über fünf Transaktionen vom 07.07.2025 bis 19.09.2025 abgeschlossen hat, wobei die Bruttoserlöse pro Transaktion angegeben werden. Das Form 144 enthält die Erklärung des Verkäufers, dass keine nicht offengelegten materiellen negativen Informationen existieren, und erfüllt die Offenlegungsvorschriften der Rule 144.
تقدّم SOPHiA GENETICS SA (SOPH) نموذج Form 144 يفيد بعرض بيع مقترح لـ 6,833 سهماً عاديةً بقيمة سوقية إجمالية قدرها 30,543.51 دولار أمريكي ليتم بيعها تقريباً في 03/10/2025 في ناسداك. تم شراء الأسهم كـ Restricted Stock Units في 02/10/2025 من المصدر وتم تسجيل الدفع في 02/10/2025. يُظهر الملف أن البائع أكمل سابقاً مبيعات وفقاً للقاعدة 10b5-1 بإجمالي 5,337 سهماً عبر خمس معاملات من 07/07/2025 إلى 19/09/2025، مع الإيرادات الإجمالية الموضحة لكل معاملة. يشمل Form 144 أيضاً إقرار البائع بأنه لا توجد معلومات سلبية مادية غير مكشوفة ويتوافق مع متطلبات إفصاح القاعدة 144.
SOPHiA GENETICS SA (SOPH) 提交 Form 144,通知拟在 NASDAQ 于大约 2025/10/03 以总市值 30,543.51 美元出售 6,833 股普通股。该等股票于 2025/10/02 以受限股票单位(Restricted Stock Units)方式从发行方取得,付款亦于 2025/10/02 记录。申报显示,卖方此前已通过 Rule 10b5-1 的交易完成 5,337 股,跨越 5 笔交易,时间为 2025/07/07 至 2025/09/19,每笔交易的毛收入如交易所示。Form 144 包含卖方声明:不存在未披露的重大不利信息,且符合 Rule 144 的披露要求。
Positive
  • Compliance with Rule 144 filing for proposed sale of 6,833 shares (aggregate $30,543.51)
  • Acquisition documented as Restricted Stock Units on 10/02/2025, showing clear basis for sale eligibility
Negative
  • Insider selling activity: prior Rule 10b5-1 sales of 5,337 shares between 07/07/2025 and 09/19/2025
  • Sale size relative to outstanding shares: 6,833 vs 67,579,560 outstanding (small but disclosed insider liquidation)

Insights

TL;DR: Insider intends to sell newly vested 6,833 RSU shares worth $30,543.51 on or about 10/03/2025.

The filing discloses that the securities were acquired as Restricted Stock Units on 10/02/2025, indicating a recent vesting or issuance event explicitly documented in the notice. The planned sale is being reported under Rule 144, which is the standard compliance path for restricted or control securities becoming eligible for public sale.

The archive of Rule 10b5-1 sales shows the same account sold 5,337 shares in five transactions between 07/07/2025 and 09/19/2025, with per-transaction gross proceeds listed in the filing. That history confirms recent, disclosed offloading activity by the same holder.

SOPHiA GENETICS SA (SOPH) presenta un modulo Form 144 che segnala una vendita proposta di 6.833 azioni ordinarie per un valore di mercato aggregato di 30.543,51 USD da vendere circa il 03/10/2025 su NASDAQ. Le azioni sono state acquisite come Restricted Stock Units il 02/10/2025 dall'emittente e il pagamento è stato registrato il 02/10/2025. La presentazione mostra che il venditore ha precedentemente completato vendite ai sensi della Rule 10b5-1 per un totale di 5.337 azioni attraverso cinque transazioni dal 07/07/2025 al 19/09/2025, generando proventi lordi indicati per transazione. Il Form 144 include la dichiarazione del venditore che non esistono informazioni materiali avverse non divulgate e si conforma ai requisiti di disclosure della Rule 144.
SOPHiA GENETICS SA (SOPH) presenta un Formulario 144 que notifica una venta propuesta de 6,833 acciones ordinarias con un valor de mercado agregado de 30,543.51 USD a venderse aproximadamente el 03/10/2025 en NASDAQ. Las acciones se adquirieron como Restricted Stock Units el 02/10/2025 del emisor y el pago se registró el 02/10/2025. La presentación muestra que el vendedor previamente completó ventas según la Regla 10b5-1 por un total de 5,337 acciones en cinco transacciones desde el 07/07/2025 al 19/09/2025, con los ingresos brutos mostrados por cada transacción. El Formulario 144 incluye la declaración del vendedor de que no existen informaciones materiales adversas no divulgadas y cumple con los requisitos de divulgación de la Regla 144.
SOPHiA GENETICS SA (SOPH)는 Form 144를 제출하며 NASDAQ에서 약 10/03/2025에 매도될 예정인 6,833주의 보통주를 총시장가치 30,543.51달러로 제시합니다. 이 주식은 발행회사로부터 2025년 10월 2일에 Restricted Stock Units로 취득되었고, 대금은 2025년 10월 2일에 기록되었습니다. 신고서는 매도인이 이전에 2025년 7월 7일부터 2025년 9월 19일까지 다섯 건에 걸친 5,337주에 대한 Rule 10b5-1 매도를 완료했으며, 거래별로 총 수익이 제시되어 있음을 보여줍니다. Form 144에는 매도인이 비공개의 주요 악재 정보가 존재하지 않는다는 진술이 포함되어 있으며 Rule 144 공시 요건에 부합합니다.
SOPHiA GENETICS SA (SOPH) dépose un formulaire Form 144 qui notifie une vente proposée de 6 833 actions ordinaires d'une valeur marchande globale de 30 543,51 USD à vendre approximativement le 03/10/2025 sur le NASDAQ. Les actions ont été acquises sous forme de Restricted Stock Units le 02/10/2025 auprès de l’émetteur et le paiement a été enregistré le 02/10/2025. Le dépôt indique que le vendeur a précédemment effectué des ventes en vertu de la règle 10b5-1 totalisant 5 337 actions réparties sur cinq transactions du 07/07/2025 au 19/09/2025, générant les produits bruts indiqués par transaction. Le Form 144 comprend la déclaration du vendeur selon laquelle il n’existe aucune information matérielle défavorable non divulguée et est conforme aux exigences de divulgation de la règle 144.
SOPHiA GENETICS SA (SOPH) reicht ein Formular Form 144 ein, das einen vorgeschlagenen Verkauf von 6.833 Stammaktien mit einem Gesamtsmarktwert von 30.543,51 USD ankündigt, der voraussichtlich am 03.10.2025 an der NASDAQ verkauft wird. Die Aktien wurden am 02.10.2025 vom Emittenten als Restricted Stock Units erworben und die Zahlung wurde am 02.10.2025 verbucht. Die Einreichung zeigt, dass der Verkäufer zuvor Rule 10b5-1-Verkäufe in Höhe von insgesamt 5.337 Aktien über fünf Transaktionen vom 07.07.2025 bis 19.09.2025 abgeschlossen hat, wobei die Bruttoserlöse pro Transaktion angegeben werden. Das Form 144 enthält die Erklärung des Verkäufers, dass keine nicht offengelegten materiellen negativen Informationen existieren, und erfüllt die Offenlegungsvorschriften der Rule 144.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What is the amount of SOPH shares proposed for sale in the Form 144?

The Form 144 reports a proposed sale of 6,833 common shares with an aggregate market value of $30,543.51.

When were the shares to be sold acquired according to the filing?

The shares were acquired as Restricted Stock Units on 10/02/2025, with payment recorded on the same date.

On what date is the planned sale scheduled?

The approximate date of sale listed is 10/03/2025 on NASDAQ.

Does the filing show prior sales by the same person?

Yes. The filing lists five Rule 10b5-1 sales totaling 5,337 shares between 07/07/2025 and 09/19/2025, with gross proceeds per transaction disclosed.

What assurance does the seller provide about undisclosed information?

By signing the notice, the seller represents they do not know any material adverse information about the issuer that has not been publicly disclosed.
Sophia Genetics Sa

NASDAQ:SOPH

SOPH Rankings

SOPH Latest News

SOPH Latest SEC Filings

SOPH Stock Data

302.08M
63.21M
6.46%
48.2%
0.06%
Health Information Services
Healthcare
Link
Switzerland
Rolle